Aethlon Medical, Inc. announced its financial results for the fiscal third quarter ended December 31, 2024, on February 12, 2025. The company reported a cash balance of approximately $4.8 million as of the quarter's end.
Consolidated operating expenses for the quarter decreased by approximately $1.8 million, or 50%, to $1.8 million compared to $3.6 million in the prior-year period. This reduction was primarily driven by a $1.3 million decrease in payroll and related expenses, a $300,000 decrease in professional fees, and a $200,000 decrease in general and administrative expenses.
The company achieved a key milestone with the successful treatment of the first patient in its Australian oncology trial on January 29, 2025, with no device-related issues. A protocol amendment was approved at all three Australian clinical sites, allowing for patient enrollment only after confirmed non-response to anti-PD-1 therapy and eliminating the two-month run-in period, which is expected to accelerate trial timelines and improve enrollment speed. The third Australian site, Genesis Care / Royal North Shore Hospital, is expected to begin enrollment following a Site Initiation Visit on February 14, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.